GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (NAS:CSCI) » Definitions » Debt-to-Revenue

CSCI (Cosciens Biopharma) Debt-to-Revenue : 0.22 (As of Sep. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cosciens Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.41 Mil. Cosciens Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.21 Mil. Cosciens Biopharma's annualized Revenue for the quarter that ended in Sep. 2024 was $7.48 Mil. Cosciens Biopharma's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.22.


Cosciens Biopharma Debt-to-Revenue Historical Data

The historical data trend for Cosciens Biopharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma Debt-to-Revenue Chart

Cosciens Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.20 0.15 0.14 0.23

Cosciens Biopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.32 0.19 0.18 0.22

Competitive Comparison of Cosciens Biopharma's Debt-to-Revenue

For the Biotechnology subindustry, Cosciens Biopharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Debt-to-Revenue falls into.



Cosciens Biopharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cosciens Biopharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.299 + 1.396) / 7.262
=0.23

Cosciens Biopharma's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.405 + 1.211) / 7.484
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Cosciens Biopharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosciens Biopharma Business Description

Traded in Other Exchanges
Address
c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, Toronto, ON, CAN, M5K 1E7
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.

Cosciens Biopharma Headlines